However, in the phase III BEACON CRC trial, encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (anti-EGFR monoclonal antibody) significantly improved the OS and ORR of patients with BRAF V600E mutant mCRC compared to the current standard chemotherapy, and its safety is consistent with the known safety of each drug [33]. This evidence concerns the gene BRAF and colorectal carcinoma.